Nebenwirkungen · Tenkasi (previously Orbactiv)
Tenkasi 400 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7–8
HOS-131346 · Präparat HOS-097053
7 Respiratory, thoracic and mediastinal disorders Uncommon Bronchospasm, wheezing, dyspnoea* Rare Hypoxia* Gastrointestinal disorders Common Nausea, vomiting, diarrhoea, constipation Uncommon Abdominal pain* Hepatobiliary disorders Common Liver function test abnormal (Alanine aminotransferase increased, Aspartate aminotransferase increased) Uncommon Blood bilirubin increased Skin and subcutaneous tissue disorders Common Urticaria, rash, pruritus Uncommon Leucocytoclastic vasculitis, angioedema, erythema multiforme, flushing Musculoskeletal and connective tissue disorders Common Myalgia Uncommon Tenosynovitis Rare Back pain*, neck pain* General disorders and administration site conditions Common Infusion site reactions** Uncommon Chest pain*, pyrexia* Rare Chest discomfort*, chills* *These reactions may be infusion-related (see section 4.4) ** Infusion site reactions includes: infusion site phlebitis, infusion site erythema, extravasation, induration, pruritus, rash, oedema peripheral.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-20T11:00:00Z · SHA-256 d20812154b71852f20873c58aef9e7d64a64378ec49b98460d5d2cd5fe13bf59 · Passage 6a93511f3f6cdce16f8c2773595c690da9104ed6f1fbd3c6ff4ce4db37073685 · Zeichen 2108–3926 im Abschnitt